Table 1:
Characteristics of Included Studies
| Authors / Year | Study Years | Study Type and Instrument | Average age | % Female | Data Source | Countries |
|---|---|---|---|---|---|---|
| Chen 2014 | 2007–2013 | Longitudinal study | 58 | 42 | Institutional databases | USA |
| Cooley 2007 | 2002–2006 | Prospective survey | 65 | 100 | Patients, 5 centers | USA |
| Cooley 2009 | 2002–2006 | Prospective survey | 63 | 57.5 | Patients, 4 centers | USA |
| deBruin-Visser 2012 | 2003–2005 | Prospective | 55.7 | 46 | Patients, 1 center | Netherlands |
| Farley 2016 | 2010–2011 | Prospective survey | 69 | 45 | Patients, 1 center | UK |
| Guimond 2017 | NR | Prospective cohort | 54 | 48 | Patients, 1 center | Canada |
| Humphris 2004 | 1996–1998 | Longitudinal design | 58.3 | 30 | Patients, 1 center | Scotland & UK |
| Krebs 2019 | NR | RCT | 57.1 | 71 | Patients, 1 center | USA |
| Maher 2003 | NR | Prospective survey | 59 | 39 | Patients, 1 center | USA |
| Martinez 2018 | 2012–2018 | RCT | 54.9 | 51 | Patients, 1 center | USA |
| Matulewicz 2021 | 2014–2018 | Cross-sectional | NR | NR | National Health Interview Survey | USA |
| Naresh 2020 | NR | Cross-sectional | NR | 8.6 | Patients, 1 center | India |
| Ostroff 2013 | NR | RCT | 55.9 | 53 | Patients, 1 center | USA |
| Ostroff 1995 | 1991–1992 | Cross-sectional | 61.5 | 33 | Patients, 1 center | USA |
| Park 2020 | 2013–2017 | RCT | 58.3 | 56 | Patients, 2 centers | USA |
| Paul 2019 | 2006 | Longitudinal study | NR | NR | Patients, 1 center | Australia |
| SandersonCox 2002 | 1994–1999 | Prospective study | 62.7 | 37 | North Central Cancer Treatment Group Trial, Patients | USA |
| Schnoll 2003 | NR | Longitudinal study | 57 | 49 | Patients, 1 center | USA |
| Schnoll 2002 | NR | Cross-sectional | 57 | 49 | Patients, 1 center | USA |
| Sheikh 2021 | 2007–2020 | Prospective cohort | 61.3 | 11.4 | Patients, 2 centers | Russia |
| Simmons 2013 | 2008–2009 | Longitudinal study | 58.3 | 43 | Patients, 1 center | USA |
| Simmons 2020 | 2012–2020 | 2-arm, parallel design | 55 | 51.8 | Patients, 1 center | USA |
| Smailey 2021 | 2016–2019 | RCT | 60 | 34 | Patients, 3 centers | Lebanon |
| Smith 2020 | 2018–2020 | Explanatory sequential mixed methods design | 60 | 15 | 5-year prospective single institution cohort study | Australia |
| Smith 2021 | 2018–2020 | Explanatory sequential mixed methods design | 60 | 15 | 5-year prospective single institution cohort study | Australia |
| Tomek 2003 | 1985–2000 | Retrospective study | NR | NR | Institutional Database, 1 center | USA |
| Vitzthum 2015 | 2011–2013 | Retrospective study | 68.7 | 36.6 | Patients, 1 center | Germany |
| Walker 2004 | 2000 | Retrospective study | 65 | 42 | Cancer Registry, Patients, 1 center | USA |
| Walker 2006 | 2001–2005 | Longitudinal study | 58.5 | 52 | Patients, 2 centers | USA |
NR=not reported, USA=United States of America, UK=United Kingdom, RCT=randomized controlled trial